EGFR and lung adenocarcinoma: Improving immunotherapy efficacy for EGFR‐negative lung adenocarcinoma (LUAD) patients remains a critical challenge, and the therapeutic effect of immunotherapy is largely determined by the tumor microenvironment (TME).